Try a new search

Format these results:

Searched for:

in-biosketch:true

person:mayerm04

Total Results:

137


18F FDG PET/MRI with hepatocyte-specific contrast agent for M staging of rectal cancer: a primary economic evaluation

Gassert, Felix G; Rübenthaler, Johannes; Cyran, Clemens C; Rink, Johann S; Schwarze, Vincent; Luitjens, Johanna; Gassert, Florian T; Makowski, Marcus R; Schoenberg, Stefan O; Mayerhoefer, Marius E; Tamandl, Dietmar; Froelich, Matthias F
PURPOSE:F FDG PET/MRI as an alternative imaging method to standard diagnostic workup for initial staging of rectal cancer. METHODS:F FDG PET/MRI with a hepatocyte-specific contrast agent and pelvic MRI + chest and abdominopelvic CT was created based on Markov simulations. For obtaining model input parameters, review of recent literature was performed. Willingness to pay (WTP) was set to $100,000/QALY. Deterministic sensitivity analysis of diagnostic parameters and costs was applied, and probabilistic sensitivity was determined using Monte Carlo modeling. RESULTS:F FDG PET/MRI was identified as an adequate diagnostic alternative to SCI with high robustness of results to variation of input parameters. CONCLUSION:F FDG PET/MRI was identified as a feasible diagnostic strategy for initial staging of rectal cancer from a cost-effectiveness perspective.
PMCID:8426298
PMID: 33686457
ISSN: 1619-7089
CID: 5595572

Combination of Radiomics and Machine Learning with Diffusion-Weighted MR Imaging for Clinical Outcome Prognostication in Cervical Cancer

Jajodia, Ankush; Gupta, Ayushi; Prosch, Helmut; Mayerhoefer, Marius; Mitra, Swarupa; Pasricha, Sunil; Mehta, Anurag; Puri, Sunil; Chaturvedi, Arvind
OBJECTIVES:To explore the potential of Radiomics alone and in combination with a diffusion-weighted derived quantitative parameter, namely the apparent diffusion co-efficient (ADC), using supervised classification algorithms in the prediction of outcomes and prognosis. MATERIALS AND METHODS:Retrospective evaluation of the imaging was conducted for a study cohort of uterine cervical cancer, candidates for radical treatment with chemo radiation. ADC values were calculated from the darkest part of the tumor, both before (labeled preADC) and post treatment (labeled postADC) with chemo radiation. Post extraction of 851 Radiomics features and feature selection analysis-by taking the union of the features that had Pearson correlation >0.35 for recurrence, >0.49 for lymph node and >0.40 for metastasis-was performed to predict clinical outcomes. RESULTS:The study enrolled 52 patients who presented with variable FIGO stages in the age range of 28-79 (Median = 53 years) with a median follow-up of 26.5 months (range: 7-76 months). Disease recurrence occurred in 12 patients (23%). Metastasis occurred in 15 patients (28%). A model generated with 24 radiomics features and preADC using a monotone multi-layer perceptron neural network to predict the recurrence yields an AUC of 0.80 and a Kappa value of 0.55 and shows that the addition of radiomics features to ADC values improves the statistical metrics by approximately 40% for AUC and approximately 223% for Kappa. Similarly, the neural network model for prediction of metastasis returns an AUC value of 0.84 and a Kappa value of 0.65, thus exceeding performance expectations by approximately 25% for AUC and approximately 140% for Kappa. There was a significant input of GLSZM features (SALGLE and LGLZE) and GLDM features (SDLGLE and DE) in correlation with clinical outcomes of recurrence and metastasis. CONCLUSIONS:The study is an effort to bridge the unmet need of translational predictive biomarkers in the stratification of uterine cervical cancer patients based on prognosis.
PMCID:8396356
PMID: 34449713
ISSN: 2379-139x
CID: 5595602

Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers

Fournier, Laure; Costaridou, Lena; Bidaut, Luc; Michoux, Nicolas; Lecouvet, Frederic E; de Geus-Oei, Lioe-Fee; Boellaard, Ronald; Oprea-Lager, Daniela E; Obuchowski, Nancy A; Caroli, Anna; Kunz, Wolfgang G; Oei, Edwin H; O'Connor, James P B; Mayerhoefer, Marius E; Franca, Manuela; Alberich-Bayarri, Angel; Deroose, Christophe M; Loewe, Christian; Manniesing, Rashindra; Caramella, Caroline; Lopci, Egesta; Lassau, Nathalie; Persson, Anders; Achten, Rik; Rosendahl, Karen; Clement, Olivier; Kotter, Elmar; Golay, Xavier; Smits, Marion; Dewey, Marc; Sullivan, Daniel C; van der Lugt, Aad; deSouza, Nandita M; European Society Of Radiology,
Existing quantitative imaging biomarkers (QIBs) are associated with known biological tissue characteristics and follow a well-understood path of technical, biological and clinical validation before incorporation into clinical trials. In radiomics, novel data-driven processes extract numerous visually imperceptible statistical features from the imaging data with no a priori assumptions on their correlation with biological processes. The selection of relevant features (radiomic signature) and incorporation into clinical trials therefore requires additional considerations to ensure meaningful imaging endpoints. Also, the number of radiomic features tested means that power calculations would result in sample sizes impossible to achieve within clinical trials. This article examines how the process of standardising and validating data-driven imaging biomarkers differs from those based on biological associations. Radiomic signatures are best developed initially on datasets that represent diversity of acquisition protocols as well as diversity of disease and of normal findings, rather than within clinical trials with standardised and optimised protocols as this would risk the selection of radiomic features being linked to the imaging process rather than the pathology. Normalisation through discretisation and feature harmonisation are essential pre-processing steps. Biological correlation may be performed after the technical and clinical validity of a radiomic signature is established, but is not mandatory. Feature selection may be part of discovery within a radiomics-specific trial or represent exploratory endpoints within an established trial; a previously validated radiomic signature may even be used as a primary/secondary endpoint, particularly if associations are demonstrated with specific biological processes and pathways being targeted within clinical trials. KEY POINTS: • Data-driven processes like radiomics risk false discoveries due to high-dimensionality of the dataset compared to sample size, making adequate diversity of the data, cross-validation and external validation essential to mitigate the risks of spurious associations and overfitting. • Use of radiomic signatures within clinical trials requires multistep standardisation of image acquisition, image analysis and data mining processes. • Biological correlation may be established after clinical validation but is not mandatory.
PMID: 33492473
ISSN: 1432-1084
CID: 5596112

Correction to: Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers

Fournier, Laure; Costaridou, Lena; Bidaut, Luc; Michoux, Nicolas; Lecouvet, Frederic E; de Geus-Oei, Lioe-Fee; Boellaard, Ronald; Oprea-Lager, Daniela E; Obuchowski, Nancy A; Caroli, Anna; Kunz, Wolfgang G; Oei, Edwin H; O'Connor, James P B; Mayerhoefer, Marius E; Franca, Manuela; Alberich-Bayarri, Angel; Deroose, Christophe M; Loewe, Christian; Manniesing, Rashindra; Caramella, Caroline; Lopci, Egesta; Lassau, Nathalie; Persson, Anders; Achten, Rik; Rosendahl, Karen; Clement, Olivier; Kotter, Elmar; Golay, Xavier; Smits, Marion; Dewey, Marc; Sullivan, Daniel C; van der Lugt, Aad; deSouza, Nandita M; ,
PMID: 33693997
ISSN: 1432-1084
CID: 5596192

Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Radiology Scientific Expert Panel

Becker, Anton S; Perez-Johnston, Rocio; Chikarmane, Sona A; Chen, Melissa M; El Homsi, Maria; Feigin, Kimberly N; Gallagher, Katherine M; Hanna, Ehab Y; Hicks, Marshall; Ilica, Ahmet T; Mayer, Erica L; Shinagare, Atul B; Yeh, Randy; Mayerhoefer, Marius E; Hricak, Hedvig; Vargas, H Alberto
Vaccination-associated adenopathy is a frequent imaging finding after administration of COVID-19 vaccines that may lead to a diagnostic conundrum in patients with manifest or suspected cancer, in whom it may be indistinguishable from malignant nodal involvement. To help the medical community address this concern in the absence of studies and evidence-based guidelines, this special report offers recommendations developed by a multidisciplinary panel of experts from three of the leading tertiary care cancer centers in the United States. According to these recommendations, some routine imaging examinations, such as those for screening, should be scheduled before or at least 6 weeks after the final vaccination dose to allow for any reactive adenopathy to resolve. However, there should be no delay of other clinically indicated imaging (eg, for acute symptoms, short-interval treatment monitoring, urgent treatment planning or complications) due to prior vaccination. The vaccine should be administered on the side contralateral to the primary or suspected cancer, and both doses should be administered in the same arm. Vaccination information-date(s) administered, injection site(s), laterality, and type of vaccine-should be included in every preimaging patient questionnaire, and this information should be made readily available to interpreting radiologists. Clear and effective communication between patients, radiologists, referring physician teams, and the general public should be considered of the highest priority when managing adenopathy in the setting of COVID-19 vaccination.
PMID: 33625298
ISSN: 1527-1315
CID: 5452872

Radiomics of high-resolution computed tomography for the differentiation between cholesteatoma and middle ear inflammation: effects of post-reconstruction methods in a dual-center study

Arendt, Christophe T; Leithner, Doris; Mayerhoefer, Marius E; Gibbs, Peter; Czerny, Christian; Arnoldner, Christoph; Burck, Iris; Leinung, Martin; Tanyildizi, Yasemin; Lenga, Lukas; Martin, Simon S; Vogl, Thomas J; Schernthaner, Ruediger E
OBJECTIVES/OBJECTIVE:To evaluate the performance of radiomic features extracted from high-resolution computed tomography (HRCT) for the differentiation between cholesteatoma and middle ear inflammation (MEI), and to investigate the impact of post-reconstruction harmonization and data resampling. METHODS:One hundred patients were included in this retrospective dual-center study: 48 with histology-proven cholesteatoma (center A: 23; center B: 25) and 52 with MEI (A: 27; B: 25). Radiomic features (co-occurrence and run-length matrix, absolute gradient, autoregressive model, Haar wavelet transform) were extracted from manually defined 2D-ROIs. The ten best features for lesion differentiation were selected using probability of error and average correlation coefficients. A multi-layer perceptron feed-forward artificial neural network (MLP-ANN) was used for radiomics-based classification, with histopathology serving as the reference standard (70% of cases for training, 30% for validation). The analysis was performed five times each on (a) unmodified data and on data that were (b) resampled to the same matrix size, and (c) corrected for acquisition protocol differences using ComBat harmonization. RESULTS:Using unmodified data, the MLP-ANN classification yielded an overall median area under the receiver operating characteristic curve (AUC) of 0.78 (0.72-0.84). Using original data from center A and resampled data from center B, an overall median AUC of 0.88 (0.82-0.99) was yielded, while using ComBat harmonized data, an overall median AUC of 0.89 (0.79-0.92) was revealed. CONCLUSION/CONCLUSIONS:Radiomic features extracted from HRCT differentiate between cholesteatoma and MEI. When using multi-centric data obtained with differences in CT acquisition parameters, data resampling and ComBat post-reconstruction harmonization clearly improve radiomics-based lesion classification. KEY POINTS/CONCLUSIONS:• Unenhanced high-resolution CT coupled with radiomics analysis may be useful for the differentiation between cholesteatoma and middle ear inflammation. • Pooling of data extracted from inhomogeneous CT datasets does not appear meaningful without further post-processing. • When using multi-centric CT data obtained with differences in acquisition parameters, post-reconstruction harmonization and data resampling clearly improve radiomics-based soft-tissue differentiation.
PMCID:8128805
PMID: 33277670
ISSN: 1432-1084
CID: 5475812

An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases

Husseini, Jad S; Amorim, Bárbara Juarez; Torrado-Carvajal, Angel; Prabhu, Vinay; Groshar, David; Umutlu, Lale; Herrmann, Ken; Cañamaque, Lina García; Garzón, José Ramón García; Palmer, William E; Heidari, Pedram; Shih, Tiffany Ting-Fang; Sosna, Jacob; Matushita, Cristina; Cerci, Juliano; Queiroz, Marcelo; Muglia, Valdair Francisco; Nogueira-Barbosa, Marcello H; Borra, Ronald J H; Kwee, Thomas C; Glaudemans, Andor W J M; Evangelista, Laura; Salvatore, Marco; Cuocolo, Alberto; Soricelli, Andrea; Herold, Christian; Laghi, Andrea; Mayerhoefer, Marius; Mahmood, Umar; Catana, Ciprian; Daldrup-Link, Heike E; Rosen, Bruce; Catalano, Onofrio A
BACKGROUND:MR is an important imaging modality for evaluating musculoskeletal malignancies owing to its high soft tissue contrast and its ability to acquire multiparametric information. PET provides quantitative molecular and physiologic information and is a critical tool in the diagnosis and staging of several malignancies. PET/MR, which can take advantage of its constituent modalities, is uniquely suited for evaluating skeletal metastases. We reviewed the current evidence of PET/MR in assessing for skeletal metastases and provided recommendations for its use. METHODS:We searched for the peer reviewed literature related to the usage of PET/MR in the settings of osseous metastases. In addition, expert opinions, practices, and protocols of major research institutions performing research on PET/MR of skeletal metastases were considered. RESULTS:Peer-reviewed published literature was included. Nuclear medicine and radiology experts, including those from 13 major PET/MR centers, shared the gained expertise on PET/MR use for evaluating skeletal metastases and contributed to a consensus expert opinion statement. [18F]-FDG and non [18F]-FDG PET/MR may provide key advantages over PET/CT in the evaluation for osseous metastases in several primary malignancies. CONCLUSION/CONCLUSIONS:PET/MR should be considered for staging of malignancies where there is a high likelihood of osseous metastatic disease based on the characteristics of the primary malignancy, hight clinical suspicious and in case, where the presence of osseous metastases will have an impact on patient management. Appropriate choice of tumor-specific radiopharmaceuticals, as well as stringent adherence to PET and MR protocols, should be employed.
PMID: 33619599
ISSN: 1619-7089
CID: 4806792

Positive selection as the unifying force for clonal evolution in multiple myeloma [Letter]

Diamond, Benjamin; Yellapantula, Venkata; Rustad, Even H; Maclachlan, Kylee H; Mayerhoefer, Marius; Kaiser, Martin; Morgan, Gareth; Landgren, Ola; Maura, Francesco
PMID: 33483619
ISSN: 1476-5551
CID: 4788272

Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use

Maclachlan, Kylee H; Came, Neil; Diamond, Benjamin; Roshal, Mikhail; Ho, Caleb; Thoren, Katie; Mayerhoefer, Marius E; Landgren, Ola; Harrison, Simon
For patients diagnosed with multiple myeloma (MM) there have been significant treatment advances over the past decade, reflected in an increasing proportion of patients achieving durable remissions. Clinical trials repeatedly demonstrate that achieving a deep response to therapy, with a bone marrow assessment proving negative for minimal residual disease (MRD), confers a significant survival advantage. To accurately assess for minute quantities of residual cancer requires highly sensitive methods; either multiparameter flow cytometry or next generation sequencing are currently recommended for MM response assessment. Under optimal conditions, these methods can detect one aberrant cell amongst 1,000,000 normal cells (a sensitivity of 10-6). Here, we will review the practical use of MRD assays in MM, including challenges in implementation for the routine diagnostic laboratory, standardisation across laboratories and clinical trials, the clinical integration of MRD status assessment into MM management and future directions for ongoing research.
PMID: 33674146
ISSN: 1465-3931
CID: 5596172

Functional imaging using radiomic features in assessment of lymphoma

Mayerhoefer, Marius E; Umutlu, Lale; Schöder, Heiko
Lymphomas are typically large, well-defined, and relatively homogeneous tumors, and therefore represent ideal targets for the use of radiomics. Of the available functional imaging tests, [18F]FDG-PET for body lymphoma and diffusion-weighted MRI (DWI) for central nervous system (CNS) lymphoma are of particular interest. The current literature suggests that two main applications for radiomics in lymphoma show promise: differentiation of lymphomas from other tumors, and lymphoma treatment response and outcome prognostication. In particular, encouraging results reported in the limited number of presently available studies that utilize functional imaging suggest that (1) MRI-based radiomics enables differentiation of CNS lymphoma from glioblastoma, and (2) baseline [18F]FDG-PET radiomics could be useful for survival prognostication, adding to or even replacing commonly used metrics such as standardized uptake values and metabolic tumor volume. However, due to differences in biological and clinical characteristics of different lymphoma subtypes and an increasing number of treatment options, more data are required to support these findings. Furthermore, a consensus on several critical steps in the radiomics workflow -most importantly, image reconstruction and post processing, lesion segmentation, and choice of classification algorithm- is desirable to ensure comparability of results between research institutions.
PMCID:8349521
PMID: 32634555
ISSN: 1095-9130
CID: 5596042